HC Wainwright Has Negative Estimate for Myomo Q1 Earnings

Myomo, Inc. (NYSEAMERICAN:MYO) – Stock analysts at HC Wainwright decreased their Q1 2026 earnings estimates for shares of Myomo in a research report issued to clients and investors on Tuesday, March 10th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.11) per share for the quarter, down from their previous estimate of ($0.10). The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.05) EPS and FY2029 earnings at $0.16 EPS.

A number of other research firms have also commented on MYO. Craig Hallum reiterated a “buy” rating on shares of Myomo in a research note on Tuesday. Ascendiant Capital Markets cut their price target on Myomo from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, November 21st. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Myomo presently has a consensus rating of “Buy” and a consensus target price of $7.67.

Myomo Stock Up 5.9%

Myomo stock opened at $0.71 on Thursday. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.30 and a quick ratio of 2.10. Myomo has a fifty-two week low of $0.64 and a fifty-two week high of $6.05. The firm has a fifty day moving average price of $0.86 and a two-hundred day moving average price of $0.92. The firm has a market cap of $27.48 million, a price-to-earnings ratio of -1.93 and a beta of 1.17.

Institutional Trading of Myomo

Hedge funds have recently modified their holdings of the company. State Street Corp raised its stake in shares of Myomo by 5.1% in the fourth quarter. State Street Corp now owns 399,853 shares of the company’s stock valued at $364,000 after purchasing an additional 19,563 shares in the last quarter. Nuveen LLC boosted its stake in Myomo by 66.4% during the fourth quarter. Nuveen LLC now owns 370,325 shares of the company’s stock worth $337,000 after buying an additional 147,784 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Myomo by 25.3% during the second quarter. JPMorgan Chase & Co. now owns 137,307 shares of the company’s stock worth $297,000 after buying an additional 27,739 shares in the last quarter. Centiva Capital LP acquired a new position in shares of Myomo in the 3rd quarter valued at $190,000. Finally, Jump Financial LLC lifted its holdings in shares of Myomo by 42.2% during the 2nd quarter. Jump Financial LLC now owns 87,000 shares of the company’s stock worth $188,000 after acquiring an additional 25,802 shares during the period. Institutional investors own 44.99% of the company’s stock.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.